Procurement and supply management activities are fundamental to consistent and reliable access to essential medicines and health products. To reduce the impact of CVD, action needs to be taken to improve prevention, diagnosis, care and management of CVD diseases. Affordable essential medicines and t...echnologies to manage CVD disease must be available where and when they are required. Medicines and technologies need to be managed appropriately to ensure that the correct medicines are selected, procured in the right quantities, distributed to facilities in a timely manner, and handled and stored in a way that maintains their quality. This needs to be backed up by policies that enable sufficient quantities to be procured in order to reduce cost inefficiencies, ensure the reliability and security of the distribution system, and encourage the appropriate use of these health products. In order to avoid stock-outs and the disruption of treatment, all related activities need to be conducted in a timely manner, with performance continually monitored, and prompt action taken in response to problems that may arise. Additionally, medication must be dispensed correctly and used rationally by the healthcare provider and patient alike. The purpose of this guide is to explain the necessary steps.
more
Guidelines for Treatment and Management of Heart Failure in Indonesia
JIMSA Jan.-March 2015 Vol. 28 no.1 p.47-50e
This manual aims to provide an overview of this subject to health care professionals, paramedics and other voluntary services involved in health care promotion
10th edition
The IDF Diabetes Atlas 10th edition provides detailed information on the estimated and projected prevalence of diabetes, globally, by region, country and territory, for 2021, 2030 and 2045. It draws attention to the growing impact of diabetes across the world and highlights proven and ...effective actions that governments and policy-makers must urgently take to tackle it.
more
This is an abridged version of the 2019 Standards containing the evidence-based recommendations most pertinent to primary care. The tables and figures have been renum-bered from the original document to match this version. The complete 2019 Standards of Care do...cument, including all supporting references, is available at professional.diabetes.org/standards.
This is an abridged version of the American Diabetes Association’s Standards of Medical Care in Diabetes—2019. Diabetes Care2018;42(Suppl. 1):S1–S194. The complete 2019 Standards supplement, including all supporting references, is available at professional.diabetes.org/standards.
more
Los presentes Lineamientos tecnicos del ministerio de salud de El Salvador establece las disposiciones para la prevención y control de la tuberculosis, para su aplicación por el personal del Sistema Nacional Integrado de Salud para incidir en la reducción de la morbimortalidad causada por la enfe...rmedad. Este documento tiene como enfoqe especial el tuberculosis y la diabetes. Incluye propositos de promocion de salud con la participación comunitaria para el control de la tuberculosis. Ademas propone una educacion de salud con enfasis en tuberculosis.
more
Accessed on 16.08.2022
Para ello integra:
• Las 36 recomendaciones sobre diabetes mellitus tipo 2:
1. Rastreo y diagnóstico.
2. Prevención.
3. Educación diabetológica para el automanejo.
4. Metas de control glucémico.
5. Tratamiento: estilo de vida saludable y tratamiento farmacoló...gico.
6. Automonitoreo glucémico.
• Recomendaciones aportadas por otras guías de práctica clínica y lineamientos
del MSN (se identifican como REx).
• Textos explicativos, cuadros, algoritmos y otras herramientas prácticas, para
facilitar su implementación.
more
In 2014, the World Heart Federation (WHF) launched
an initiative to develop a series of Roadmaps [1e6]. Their
aim is to identify potential roadblocks on the pathway to
effective prevention, detection, and management of cardiovascular disease (CVD), along with evidence-based
solutions to overcome... them. The resulting documents
provide a framework to translate strategic intent into action
on integrating epidemiology, population, and cardiovascular outcome trial data into national plans for optimal
CVD management.
more
Disease epidemiology has a deeper relationship with the dynamic nature of culture. Health behaviors in general are largely shaped by the cultural norms and customs in a society. A mere identification of a behavior could be only a layer on the outer sphere of a particular disease epidemiology and the... interventional efforts to counteract such behaviors through for example public health measures could be futile and volatile, unless the deeper cultural factors are addressed.
more
Objectives Our study aimed to systematically review the literature and synthesise findings on potential associations of built environment characteristics with type 2 diabetes (T2D) in Asia.
It is now well known that there is a pandemic of Type 2 Diabetes in the world particularly in developing countries. This fact has several implications for the health care system in the developing countries because this condition is associated with metabolic and vascular complications which in turn i...ncreases the mortality and health care costs and compromises the quality and life expectancy of the society.
more
It is estimated that 422 million people in the world live with diabetes. WHO forecasts that this number will reach 622 million by 2040. The majority of people with diabetes live in developing countries. The number of people with diabetes is increasing, notably in Africa, from 3 adults among 100 peop...le in 1980 to 7 adults among 100 people in 2014.
more
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more